Firma Kuros Biosciences, Autor bei News-Research

Kuros Biosciences to showcase new MagnetOs products at NASS 2021 Annual Meeting

28. September 2021 Firma Kuros BiosciencesPosted in MedizintechnikTagged bone, bony, cells, cervical, easypack, extender, graft, kuros, magnetos, osseous, patients, posterolateral, putty, statements, with

. New products expand perioperative solutions for surgeons Data to be presented on new formulation of MagnetOs that includes a collagen carrier Kuros Biosciences (“Kuros” or the “Company”), a leader […]

Kuros Biosciences Reports Results for First Half 2021

11. August 202111. August 2021 Firma Kuros BiosciencesPosted in Finanzen / BilanzenTagged bone, checkmate, chf, ecm, fibrin, gold, implant, kuros, magnetos, patients, posterolateral, pth, statements, with, wound

. Financial Highlights CHF 29.4 million cash & cash equivalents, trade and other receivables as of June 30, 2021 Received CHF 5.5 million milestone payments from Checkmate Pharmaceuticals Acceleration of […]

Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate Pharmaceuticals

15. Juli 202115. Juli 2021 Firma Kuros BiosciencesPosted in Forschung und EntwicklungTagged ??royalty??, bone, checkmate, fibrin, graft, kuros, magnetos, pth, revenue, Royalties, statements, tlr9, vidutolimod, with, xoma

Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has entered into a royalty purchase agreement with XOMA Corporation (NASDAQ: […]

Kuros Biosciences announces publication of data on MagnetOs in eCM Journal linking MOA to enhanced predictable bone regeneration

22. Juni 202122. Juni 2021 Firma Kuros BiosciencesPosted in Forschung und EntwicklungTagged bone, cells, cervical, clinical, ecm, graft, kuros, magnetos, patients, power, spinal, statements, sur, with, wound

. First peer-reviewed article with demonstrated efficacy in preclinical and clinical studies Outlines ability of MagnetOs to deliver uniform, stable and reliable bone fusions Kuros Biosciences (SIX: KURN) today announced […]

Kuros Biosciences to present at upcoming U.S. spine conferences

17. Juni 2021 Firma Kuros BiosciencesPosted in Forschung und EntwicklungTagged bone, cns, equiva, fibrin, gold, implant, kuros, magnetos, mountain, osseous, posterolateral, pth, statements, with, wound

Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today announced that high-profile surgeons will present on the […]

Kuros Biosciences’s commercial roll-out of MagnetOs bone graft exceeds expectations

2. Juni 20219. Juni 2022 Firma Kuros BiosciencesPosted in Gesundheit & MedizinTagged any, biosciences, cells, clinical, covid, economic, fda, financial, kuros, magnetos, statements, testament, travel, with, wound

MagnetOs U.S. Q1 sales accelerate, rising 117% over Q1 2020 European distribution network expansion ahead of schedule Key commercial events in Australia, UK Kuros Biosciences (SIX: KURN), a leader […]

Kuros to receive $4 million milestone payment from Checkmate Pharmaceuticals

17. Mai 2021 Firma Kuros BiosciencesPosted in AllgemeinTagged bone, checkmate, dosing, financial, fu?r, graft, immunotherapies, kuros, patients, Payment, Royalties, statements, treatment, unresectable, with

. • Milestone triggered by Checkmate’s initiation of potential registration trial of vidutolimod (CMP-001) in patients with anti-PD-1 refractory advanced melanoma • Kuros stands to receive up to […]

Kuros Biosciences strengthens its patent position on use of Fibrin-PTH in spinal fusion

5. Mai 2021 Firma Kuros BiosciencesPosted in FirmeninternTagged biosciences, bone, clinical, derivatives, fibrin, financial, graft, kuros, market, orthobiologics, patients, pth, spinal, statements, with

Kuros Biosciences AG (SIX: KURN), a leader in next generation bone graft technologies, today announced that its subsidiary, Kuros Biosurgery AG, has been granted European patent EP 2686027, entitled ‘Pharmaceutical […]

Kuros Biosciences publishes invitation to the Annual General Meeting 2021

29. März 2021 Firma Kuros BiosciencesPosted in FirmeninternTagged bone, cells, chf, clinical, dividend, fibrin, graft, kuros, magnetos, orthobiologics, pth, spinal, statements, with, wound

Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today published the invitation and agenda for its Annual […]

Kuros Biosciences reports results for the full year 2020

18. März 2021 Firma Kuros BiosciencesPosted in Finanzen / BilanzenTagged bone, checkmate, chf, fibrin, gold, graft, kuros, magnetos, orthobiologics, patients, pth, revenues, statements, tlif, with

Financial highlights CHF 29.8 million cash & cash equivalents, trade and other receivables at December 31, 2020 Revenues increased by 58% to CHF 4.0 million Operational highlights Initiated Phase II […]